Slide 1: Q2 2026 Earnings Presentation
Q2 2026 Earnings Presentation July 30, 2026 Q2 2026 Earnings Presentation FMC CORPORATION 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements made in this presentation are forward- looking statements that are based on our current views and assumptions regarding future events, future business conditions and the outlook
Slide 3: FMC Advancing on 2026 Operational Priorities
FMC Advancing on 2026 Operational Priorities Strategic review complete; Company continues to focus on operational priorities Generate ~$1B of Improve Implement Post-Patent Grow Sales of New Proceeds for Debt Competitiveness of Rynaxypyr® Strategy Active Ingredients Paydown Core Portfolio Sale of Ind
Slide 4: Q2 2026 Results
Q2 2026 Results Q2 2026 Q2 20252 2026 VS. 2025 GAAP Revenue $867 $1,051 (17)% Revenue ex. India1 $841 (20)% GAAP Net Income (Loss) $(187) $67 $(253) Adjusted EBITDA1 $153 $207 (26)% % Revenue (ex. ’26 India) 18.1% 19.7% (160) bps GAAP EPS $(1.49) $0.53 $(2.02) Adjusted EPS1 $0.26 $0.69 (62)% Note: A
Slide 5: Regional Revenue Drivers
Q2 2026 Regional Revenue Drivers REGIONAL REVENUE BRIDGE (Excluding India)1 North $249 million Latin $278 million (-22% YoY, (-10% YoY, America -23% ex-FX) America -16% ex-FX) $1,051 • Competitive market and tight grower • Lower partner sales primary driver of $999 ($52) margins led to lower volumes
Slide 6: Adjusted EBITDA Drivers
Q2 2026 Adjusted EBITDA1 Drivers Adjusted EBITDA1 BRIDGE $207 $0 $207 $62 $6 $153 ($47) ($75) Q2 ‘25 India India Q2 ‘25 ex. Volume, Mix,… Volume, Mix, Price Cost Cost FX Q2 ‘26 Q2 '26 Q2 '25 India Q2 '25 ex. India Launches Price FX Note: Amounts in millions of USD KEY DRIVERS AT A GLANCE Volume, Mix
Slide 7: FY 2026 Financial Outlook
FY 2026 Financial Outlook FY 2026 Guidance REVENUE excl. India1 REVENUE (excl. India)1 DRIVERS • Excluding India, volume in line with prior year $3.50 billion – • 50%+ growth in new active ingredients $3.70 billion • Increase in direct sales in Brazil • Higher sales in EMEA and LATAM (7)% YoY3 • Pri
Slide 8: Q3 2026 Financial Outlook
Q3 2026 Financial Outlook Q3 2026 Guidance REVENUE excl. India1 REVENUE (excl. India)1 DRIVERS • Mid to high-single digit price decline • Growth of new active ingredients $840 million – • Lower volumes driven by North America distributors • FX neutral $900 million shifting orders to Q4 to align purc
Slide 9: Q4 2026 Financial Outlook
Q4 2026 Financial Outlook Q4 2026 Guidance REVENUE excl. India1 REVENUE (excl. India)1 DRIVERS • Higher volume due to: • Mid to high-single digit price decline $1.06 billion – o Increase in direct sales to growers in Brazil • FX neutral $1.20 billion o New active ingredients including fluindapyr-bas
Slide 10: Q2 Cash Results and 2026 Cash Flow Guidance
Q2 Cash Results and 2026 Cash Flow Guidance Q2 ’26 In Millions Q2 ‘26 Q2 ‘25 FY 2026 Guidance vs. Q2 ’25 Adjusted EBITDA1 $153 $207 $(54) $620 - $680 Cash from Operations (GAAP) $363 $66 $297 $200 - $320 Q2 Cash Results • $200M from rimisoxafen upfront Capital Additions & Other Investing Activities
Slide 11: FMC Corporation
Q2 2026 Earnings Presentation FMC CORPORATION 11
Slide 12: Modeling Assumptions for 2026
Modeling Assumptions for 2026 Appendix $275 million – 16 – 18 $1 million – Revenue: ~$90 million EBITDA: $0 million $285 million percent $3 million INTEREST EXPENSE NON-CONTROLLING INTEREST 2026 EXPECTED INDIA LOSS OF ADJUSTED TAX RATE1 CONTRIBUTION ~125.9 $160 million – $75 million – $50 – $70 mill
Slide 13: Adjusted EPS Variance
Q2 2026 Adjusted EPS1 Variance Appendix $0.69 $(0.37) $(0.07) $0.02 $(0.01) $0.26 Q2 ‘25 Adj. EBITDA1 INT. EXPENSE D&A OTHER Q2 ‘26 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation Q2 2026 Earnings Presentation FMC CORPORATION 13
Slide 14: Additional Disclaimers
Additional Disclaimers Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. No offer for sale, sale, or use of any such products is permitted prior to the issuance of t
Slide 15: Q2 2026 Earnings Presentation
Copyright © 2026, FMC Corporation. All Rights Reserved. Q2 2026 Earnings Presentation FMC CORPORATION 15